Skip to main navigation
Skip to search
Skip to main content
University of Edinburgh Research Explorer Home
Help & FAQ
Link opens in a new tab
Search content at University of Edinburgh Research Explorer
Home
Research output
Profiles
Research units
Projects
Datasets
Prizes
Activities
Press/Media
Equipment
The impact of 27-hydroxycholesterol on endometrial cancer proliferation
Philippa TK Saunders
, Frances Collins
, Fiona Cousins
,
Arantza Esnal-Zufiaurre
,
Douglas A Gibson
School of Regeneration and Repair
Centre for Inflammation Research
Edinburgh Imaging
Royal (Dick) School of Veterinary Studies
Research output
:
Contribution to conference
›
Abstract
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The impact of 27-hydroxycholesterol on endometrial cancer proliferation'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
26 Hydroxycholesterol
100%
Uterine Cancer
100%
Liver X Receptor
72%
Cell Proliferation
27%
3 [3 [[2 Chloro 3 (Trifluoromethyl)benzyl](2 Diphenylethyl)amino]propoxy]phenylacetic Acid
27%
Cancer
18%
Incubation
9%
Epithelial Cell
9%
Disease Severity
9%
Postmenopause
9%
Bioavailability
9%
Receptor Expression
9%
Hypercholesterolemia
9%
Abdominal Hysterectomy
9%
Endogenous Agonist
9%
Cholesterol Metabolism
9%
CYP27A1
9%
Liver X Receptor Agonist
9%
Selective Estrogen Receptor Modulator
9%
Treatment of Advanced Disease
9%
Cell Line
9%
Metabolite
9%
Enzymes
9%
Reporter Gene
9%
Luciferase
9%
Cholesterol
9%
Therapeutic Target
9%
Pharmacology, Toxicology and Pharmaceutical Science
Endometrium Cancer
100%
26 Hydroxycholesterol
100%
Liver X Receptor
72%
3 [3 [[2 Chloro 3 (Trifluoromethyl)benzyl](2 Diphenylethyl)amino]propoxy]phenylacetic Acid
27%
Cholesterol
18%
Luciferase
9%
Disease Severity
9%
Bioavailability
9%
Hypercholesterolemia
9%
Diseases
9%
Selective Estrogen Receptor Modulator
9%
Endogenous Agonist
9%
Liver X Receptor Agonist
9%
CYP27A1
9%
Enzyme
9%
Immunology and Microbiology
Uterine Cancer
100%
Endometrium Cancer
100%
Cell Proliferation
27%
Agonist
18%
Reporter Gene
9%
Cell Line
9%
Metabolite
9%
Postmenopause
9%
Cholesterol Metabolism
9%
Therapeutic Target
9%